摘要:
Novel glutamate receptor antagonists represented by the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein Z is an alicyclic fused ring having 5 to 7 carbon atoms; R.sup.1 is hydrogen, an alkyl or an arylalkyl; and A is O, CH.sub.2, NR.sup.4, CH.sub.2 NR.sup.4, CN, tetrazole or CO wherein R.sup.4 is hydrogen, alkyl, hydroxyalkyl, aminoalkyl or aralkyl, wherein (i) when A is O, CH.sub.2, NR.sup.4 or CH.sub.2 NR.sup.4 then B is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, hydroxyalkyl, alkoxy, aminoalkyl, heterocyclic, alkylheterocyclic, heterocyclic-methyl, heterocyclic-ethyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heterocyclic-carbonyl, alkylheterocyclic-carbonyl, or when A is NR.sup.4 or CH.sub.2 NR.sup.4 then B is a naturally occurring .alpha.-amino acid moiety joined by an amide bond or B joins with R.sup.4 and the nitrogen to form a four to seven membered heterocyclic ring, provided that when Z is a fused cyclohexyl ring and R.sup.4 is hydrogen then B is not hydrogen; (ii) when A is CN then B is not present and Z is not a fused cyclohexyl ring; (iii) when A is tetrazole then B is hydrogen or alkyl having 1 to 6 carbon atoms; and (iv) when A is CO then B is hydroxy, alkoxy, aralkoxy, alkyl having 1 to 6 carbon atoms, aralkyl, NR.sup.7 R.sup.8.
摘要翻译:由式“IMAGE”表示的新型谷氨酸受体拮抗剂或其药学上可接受的盐,其中Z是具有5至7个碳原子的脂环稠合环; R1是氢,烷基或芳基烷基; 并且A是O,CH 2,NR 4,CH 2 NR 4,CN,四唑或CO,其中R 4是氢,烷基,羟基烷基,氨基烷基或芳烷基,其中(i)当A是O,CH 2,NR 4或CH 2 NR 4时,B是氢, 烯基,炔基,芳基,芳烷基,羟基烷基,烷氧基,氨基烷基,杂环,烷基杂环,杂环 - 甲基,杂环 - 乙基,烷基羰基,环烷基羰基,芳基羰基,芳烷基羰基,杂环羰基,烷基杂环羰基,或当A为NR4或CH2NR4时 B是通过酰胺键连接的天然存在的α-氨基酸部分或B与R 4和氮连接形成4至7元杂环,条件是当Z为稠合环己基环且R 4为氢时,B不为 氢; (ii)当A为CN时,B不存在,Z不为稠环己基环; (iii)当A是四唑时,B是氢或具有1至6个碳原子的烷基; 和(iv)当A是CO时,B是羟基,烷氧基,芳烷氧基,具有1至6个碳原子的烷基,芳烷基,NR 7 R 8。
摘要:
The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R1 is and A1, A2, A3, A4, X, Z, Z′, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
摘要:
The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
摘要:
The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
摘要:
The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.